

Gianluca Masi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1595248/publications.pdf>

Version: 2024-02-01

130
papers

10,169
citations

117453

34
h-index

34900

98
g-index

132
all docs

132
docs citations

132
times ranked

11310
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2022, 103, 102326.	3.4	6
2	Upper transversal hepatectomy with double hepatic vein resection and reconstruction to treat colorectal cancer liver metastases at the hepatocaval confluence: a strategy to achieve R0 liver-sparing resection. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1741-1750.	0.8	3
3	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	3
4	Early modulation of Angiotensin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 165, 116-124.	1.3	6
5	The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features. <i>Cancer Treatment Reviews</i> , 2022, 106, 102382.	3.4	9
6	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 167, 23-31.	1.3	8
7	Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. <i>Epigenomics</i> , 2022, 14, 507-517.	1.0	4
8	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 170, 64-72.	1.3	3
9	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. <i>British Journal of Cancer</i> , 2022, 127, 957-967.	2.9	6
10	Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO. <i>Journal of Clinical Oncology</i> , 2022, 40, 2878-2888.	0.8	24
11	Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy?. <i>Updates in Surgery</i> , 2022, 74, 1327-1335.	0.9	3
12	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , 2021, 124, 183-190.	2.9	7
13	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135.	3.4	2
14	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021, 26, 302-309.	1.9	9
15	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 370-379.	4.2	31
16	Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. <i>Liver International</i> , 2021, 41, 1389-1397.	1.9	45
17	Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3665-3671.	1.2	12
18	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. <i>Hepatology Research</i> , 2021, 51, 796-802.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. <i>Hpb</i> , 2021, 23, 915-920.	0.1	14
20	Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2021, 20, 314-317.	1.0	12
21	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , 2021, 125, 839-845.	2.9	9
22	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 153, 16-26.	1.3	5
23	Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. <i>Hepatology Research</i> , 2021, 51, 1229-1241.	1.8	33
24	Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. <i>Targeted Oncology</i> , 2021, 16, 653-661.	1.7	0
25	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 155, 73-84.	1.3	13
26	Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. <i>Journal of Clinical Oncology</i> , 2021, 39, e002996.		24
27	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. <i>Cancer Management and Research</i> , 2021, Volume 13, 9379-9389.	0.9	31
28	About the Recently Published Paper on <i>JAMA Oncology</i> "Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial" <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1418-1419.	0.9	0
29	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3314-3324.	0.8	139
30	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020, 21, 497-507.	5.1	196
31	Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center. <i>In Vivo</i> , 2020, 34, 2061-2066.	0.6	3
32	Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1305-1314.	0.9	41
33	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. <i>Targeted Oncology</i> , 2020, 15, 115-126.	1.7	15
34	HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer. <i>Oncologist</i> , 2020, 25, 886-893.	1.9	27
35	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. <i>Cancers</i> , 2020, 12, 1022.	1.7	16
36	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019, 18, 116-124.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. <i>Biochemical Pharmacology</i> , 2019, 164, 94-105.	2.0	14
38	Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. <i>European Journal of Cancer</i> , 2019, 109, 175-182.	1.3	25
39	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. <i>European Journal of Cancer</i> , 2019, 110, 32-41.	1.3	25
40	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. <i>ESMO Open</i> , 2019, 4, e000496.	2.0	3
41	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019, 120, 165-171.	2.9	279
42	Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. <i>JAMA Oncology</i> , 2019, 5, 343.	3.4	280
43	Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2018, 36, 709-714.	1.2	8
44	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2018, 4, 529.	3.4	87
45	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018, 104, 476-479.	0.6	14
46	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018, 23, 1178-1187.	1.9	46
47	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable <i>RAS</i> and <i>BRAF</i> wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000403.	2.0	20
48	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, e617-e629.	1.0	54
49	Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017, 116, 318-323.	2.9	29
50	First-line therapy for mCRC – the influence of primary tumour location on the therapeutic algorithm. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 113-113.	12.5	35
51	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	6.3	2,771
52	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in <i>RAS/BRAF</i> wild-type colorectal cancer patients receiving irinotecan/cetuximab. <i>British Journal of Cancer</i> , 2017, 117, 315-321.	2.9	19
53	Techniques of parenchyma-sparing hepatectomy for the treatment of tumors involving the hepatocaval confluence: A reliable way to assure an adequate future liver remnant volume. <i>Surgery</i> , 2017, 162, 483-499.	1.0	13
54	Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2017, 73, 74-84.	1.3	54

#	ARTICLE	IF	CITATIONS
55	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	5.1	293
56	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017, 17, 408.	1.1	28
57	The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres. <i>Annals of Surgical Oncology</i> , 2017, 24, 2465-2473.	0.7	42
58	Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2017, 16, e61-e72.	1.0	18
59	Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. <i>Anticancer Research</i> , 2017, 37, 315-320.	0.5	21
60	Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. <i>Oncology</i> , 2016, 91, 283-288.	0.9	5
61	Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 988-994.	1.9	94
62	Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. <i>Future Oncology</i> , 2016, 12, 901-908.	1.1	14
63	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1 α Final results of the ALICE-2 study. <i>Journal of Clinical Oncology</i> , 2016, 34, 280-280.	0.8	13
64	Pharmacoeigenetics in gastrointestinal tumors em MGMT em methylation and beyond. <i>Frontiers in Bioscience - Elite</i> , 2016, 8, 170-180.	0.9	11
65	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 874.	1.1	10
66	Tivantinib, a New Option for Second-line Treatment of Advanced Hepatocellular Carcinoma? The Experience of Italian Centers. <i>Tumori</i> , 2015, 101, 139-143.	0.6	6
67	Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database. <i>International Journal of Biological Markers</i> , 2015, 30, 65-72.	0.7	8
68	Minor-but-Complex Liver Resection. <i>Medicine (United States)</i> , 2015, 94, e1188.	0.4	19
69	First-line chemotherapy for mCRC—a review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 607-619.	12.5	138
70	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2719-2725.	0.9	66
71	TAS-102 for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1283-1292.	1.1	12
72	Role of <i>NRAS</i> mutations as prognostic and predictive markers in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2015, 136, 83-90.	2.3	126

#	ARTICLE	IF	CITATIONS
73	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. Journal of Clinical Oncology, 2015, 33, 657-657.	0.8	17
74	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2014, 9, e105268.	1.1	33
75	Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. Future Oncology, 2014, 10, 285-304.	1.1	13
76	Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?. Oncology, 2014, 86, 191-198.	0.9	18
77	Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: A systematic review. World Journal of Gastroenterology, 2014, 20, 6081.	1.4	24
78	EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Targeted Oncology, 2014, 9, 205-214.	1.7	27
79	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2014, 371, 1609-1618.	13.9	845
80	Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. Journal of Clinical Oncology, 2014, 32, TPS3664-TPS3664.	0.8	2
81	Adjuvant Systemic Chemotherapy After Putative Curative Resection of Colorectal Liver and Lung Metastases. Clinical Colorectal Cancer, 2013, 12, 188-194.	1.0	28
82	Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. Cancer Biology and Therapy, 2013, 14, 467-468.	1.5	5
83	Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial.. Journal of Clinical Oncology, 2013, 31, e14577-e14577.	0.8	2
84	Prognostic Value of CD133 Caused by Mutant K-Ras and B-Raf Letter. Clinical Cancer Research, 2012, 18, 4473-4473.	3.2	0
85	A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients. Oncology, 2012, 82, 75-82.	0.9	7
86	Resectable liver metastases from colorectal cancer: where we are now and where do we go from here?. Colorectal Cancer, 2012, 1, 397-411.	0.8	0
87	Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. Clinical Colorectal Cancer, 2012, 11, 71-76.	1.0	17
88	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. Current Colorectal Cancer Reports, 2012, 8, 153-160.	1.0	0
89	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis, 2012, 15, 275-286.	3.7	61
90	Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2011, 11, 519-531.	1.4	3

#	ARTICLE	IF	CITATIONS
91	Anti-HER agents in gastric cancer: from bench to bedside. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 369-383.	8.2	73
92	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011, 11, 247.	1.1	69
93	Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 243-251.	2.0	31
94	Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches. <i>Future Oncology</i> , 2011, 7, 1299-1323.	1.1	14
95	Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis. <i>Journal of the National Cancer Institute</i> , 2011, 103, 21-30.	3.0	160
96	Faithful Markers of Circulating Cancer Stem Cells: Is CD133 Sufficient for Validation in Clinics?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3487-3488.	0.8	14
97	Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients. <i>Current Cancer Drug Targets</i> , 2010, 10, 37-45.	0.8	12
98	Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 559-566.	1.1	5
99	Palliative treatment of unresectable metastatic colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 63-77.	0.9	18
100	Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. <i>Lancet Oncology</i> , The, 2010, 11, 845-852.	5.1	234
101	Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases. <i>Annals of Surgery</i> , 2009, 249, 420-425.	2.1	213
102	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. <i>BMC Cancer</i> , 2009, 9, 303.	1.1	66
103	Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 132-134.	1.1	9
104	Refractory neuroendocrine tumor response to liposomal doxorubicin and capecitabine. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 670-674.	12.5	5
105	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2622-2629.	0.8	402
106	Long-Term Outcome of Unresectable Metastatic Colorectal Cancer: Does Adjuvant Chemotherapy Play a Role After Resection?. <i>Annals of Surgery</i> , 2009, 250, 655.	2.1	0
107	First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients. , 2009, , 285-293.		0
108	Triplet Combination of Fluoropyrimidines, Oxaliplatin, and Irinotecan in the First-Line Treatment of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 7-14.	1.0	15

#	ARTICLE	IF	CITATIONS
109	Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1427-1434.	0.8	124
110	Optimal approach to potentially resectable liver metastases from colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1533-1539.	1.1	4
111	High Concordance of <i>KRAS</i> Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice. <i>Oncologist</i> , 2008, 13, 1270-1275.	1.9	218
112	EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. <i>Pharmacogenomics</i> , 2008, 9, 55-69.	0.6	12
113	First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?. <i>Current Opinion in Oncology</i> , 2008, 20, 459-465.	1.1	11
114	Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. <i>Journal of Clinical Oncology</i> , 2007, 25, 1670-1676.	0.8	1,083
115	Vascular Endothelial Growth Factor Levels in Immunodepleted Plasma of Cancer Patients As a Possible Pharmacodynamic Marker for Bevacizumab Activity. <i>Journal of Clinical Oncology</i> , 2007, 25, 1816-1818.	0.8	56
116	Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 1247-1254.	0.8	250
117	Chemotherapy intensification. <i>Current Colorectal Cancer Reports</i> , 2007, 3, 116-122.	1.0	0
118	Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2006, 13, 58-65.	0.7	156
119	Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer. <i>Tumori</i> , 2006, 92, 384-388.	0.6	17
120	Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 585-593.	1.1	13
121	Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. <i>Tumori</i> , 2006, 92, 384-8.	0.6	7
122	A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed. <i>Clinical Cancer Research</i> , 2004, 10, 1657-1663.	3.2	23
123	5-Fluorouracil Administered as a 48-Hour Semiintermittent Infusion in Combination With Leucovorin, Cisplatin and Epirubicin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 101-105.	0.6	2
124	Biweekly Chemotherapy With Oxaliplatin, Irinotecan, Infusional Fluorouracil, and Leucovorin: A Pilot Study in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 4006-4014.	0.8	148
125	Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients. <i>Journal of Clinical Oncology</i> , 2001, 19, 3456-3462.	0.8	51
126	5-Fluorouracil Administered as a 48-Hour Chronomodulated Infusion in Combination with Leucovorin and Cisplatin: A Randomized Phase II Study in Metastatic Colorectal Cancer. <i>Oncology</i> , 2001, 61, 28-35.	0.9	9

#	ARTICLE	IF	CITATIONS
127	Oral Doxifluridine in Advanced Hepatocellular Carcinoma: A Phase II Study. <i>Oncology</i> , 2000, 59, 204-209.	0.9	7
128	Infusions of Fluorouracil and Leucovorin: Effects of the Timing and Semi-Intermittency of Drug Delivery. <i>Oncology</i> , 1999, 57, 195-201.	0.9	22
129	Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 159-163.	1.1	14
130	Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. , 1999, 86, 470-476.		30